Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Consider This in Older People Undergoing Allo-SCT
Biol Blood Marrow Transplant; ePub 2017 Jul 19; Jakubowski, et al
T-cell depleted allogeneic hematopoietic stem cell transplantation appears to work just as well in older patients with hematologic malignancies as it does in their younger counterparts, according to a retrospective study involving 214 individuals. Participants were treated at a single center and were aged ≥55 years. 7 in every 10 had myeloid diseases, and most with acute leukemia were in remission. Investigators reviewed the center’s experience with these patients over 11 years. Among the results:
- With median follow-up of 70 months among survivors, overall survival rate was 44%.
- Relapse-free survival rate was 41%.
- Cumulative incidence of non-relapse mortality at day+100 was only 10%.
- 9% had acute graft versus host disease (GVHD) at day+100.
- 7% had chronic GVHD at 2 years.
- Median Karnofsky Performance Scale for patients >2 years posttransplant was 90.
The authors noted that these results are similar to those seen in younger individuals.
Jakubowski A, Petrlik E, Maloy M, et al. T-cell depletion as an alternative approach for patients >55 years undergoing allogeneic stem cell transplantation as curative therapy for hematologic malignancies. [Published online ahead of print July 19, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.06.024.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al